GOSS is expected to report earnings to rise 20.14% to -16 cents per share on March 21
Q4'24
Est.
$-0.17
Q3'24
Beat
by $0.01
Q2'24
Missed
by $0.29
Q1'24
Est.
$-0.19
Q4'23
Est.
$-0.21
The last earnings report on November 08 showed earnings per share of -14 cents, beating the estimate of -15 cents. With 150.55K shares outstanding, the current market capitalization sits at 197.71M.
a company, which engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology